Tom Lillie

Tom Lillie has extensive work experience in the healthcare industry. Tom is currently the Chief Medical Officer at Grey Wolf Therapeutics since May 2023. Prior to this, they held the same position at Akamis Bio from January 2023 to the present, and from January 2020 to January 2023. Before joining Akamis Bio, Tom worked at MSD as the Vice President, Head of Oncology Global Medical Affairs from April 2018 to December 2019, and as the Vice President, Head of European Clinical Development from February 2016 to December 2019. Prior to MSD, they worked at Amgen in various roles such as Therapeutic Area Head, Oncology from September 2008 to January 2016, Global Development Leader, Aranesp from August 2005 to August 2008, Medical Affairs Director, denosumab from January 2005 to August 2005, and Oncology Medical Leader from August 2002 to December 2004. Tom also has previous experience working at Aventis as a Medical Affairs Manager from 2000 to 2003.

Tom Lillie pursued their education in the field of Medicine, focusing on various aspects of medicine and biology. Tom completed their undergraduate studies at the University of Oxford from 1986 to 1989, earning a BA (Hons) degree in Medicine. Following their bachelor's degree, Tom Lillie proceeded to UCL (University College London) where they obtained an MD degree, specializing in Medicine, from 1992 to 1995. Additionally, they pursued a PhD in Cell Biology, specifically focusing on the study of 2nd messengers and G-proteins, at UCL from 1989 to 1992.